Hypothalamic Orexin Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Orexin neurons (also known as hypocretin neurons) are specialized hypothalamic neurons that play a critical role in regulating wakefulness, arousal, sleep-wake transitions, and energy homeostasis. These neurons degenerate selectively in narcolepsy and show dysfunction in Alzheimer's and Parkinson's diseases. [1]
| Property | Value | [2]
|----------|-------| [3]
| Cell Type Name | Hypothalamic Orexin (Hypocretin) Neurons | [4]
| Allen Atlas ID | Hypothalamus, lateral hypothalamic area (LHA), orexin-containing neurons | [5]
| Lineage | Neuropeptide neuron > Orexin/hypocretin neuron | [6]
| Marker Genes | HCRT (orexin A/B), HCRTR1, HCRTR2, MCH, PDYN | [7]
| Brain Regions | Lateral Hypothalamic Area (LHA), perifornical nucleus |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0011109 | hypocretin-secreting neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0011109 | hypocretin-secreting neuron | Exact |
Orexin neurons are located primarily in the lateral hypothalamic area (LHA) and perifornical nucleus. They are characterized by:
The orexin system consists of approximately 50,000-70,000 neurons in the human hypothalamus (each hemisphere).
Orexin neurons are the master regulators of wakefulness:
Orexin neurons project widely to:
Orexin system dysfunction contributes to AD pathophysiology:
Single-nucleus RNA sequencing of orexin neurons reveals:
| Drug | Target | Application |
|---|---|---|
| Suvorexant | HCRTR1/2 antagonist | Insomnia treatment |
| Lemborexant | HCRTR1/2 antagonist | Sleep disorders |
| Daridorexant | HCRTR1/2 antagonist | Narcolepsy/insomnia |
| Almorexant | HCRTR1/2 antagonist | Sleep disorders (withdrawn) |
The study of Hypothalamic Orexin Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Saper CB, Chou TC, Scammell TE. [The sleep switch: hypothalamic control of sleep and wakefulness](https://doi.org/10.1016/S0166-2236(00). Trends Neurosci. 2001. ↩︎ ↩︎
Peyron C, Faraco J, Rogers W, et al. A mutation in the case of early-onset narcolepsy. Brain. 2019. ↩︎ ↩︎
Thompson MD, Xhaard H, Sakurai T, et al. [Orexin/hypocretin and reward: from psychostimulants to obesity](https://doi.org/10.1016/S0079-6123(12). Prog Brain Res. 2012. ↩︎
Saper CB, Fuller PM, Pedersen NP, et al. Sleep state switching. Neuron. 2010. ↩︎
Tsunematsu T, Yamanaka A. The role of orexin/hypocretin in the regulation of sleep-wakefulness and energy homeostasis. Sleep Med Clin. 2016. ↩︎
Mahler SV, Smith RJ, Aston-Jones G. Interactions between orexin-1 and dopamine receptors in reward. Brain Res. 2020. ↩︎
Nutt DJ, Stahl SM. Orexin receptors: pharmacology and therapeutic opportunities. Handb Exp Pharmacol. 2012. ↩︎
Sakurai T. The orexin system and energy homeostasis. Front Neuroendocrinol. 2019. ↩︎